Clinical presentation and treatment of herpes zoster and postherpetic neuralgia

被引：1

作者：

Huning, S. ^{[1
]}

Werner, M. ^{[1
]}

Susok, L. ^{[1
]}

机构：

[1] Klinikum Univ Witten Herdecke, Klinikum Dortmund gGmbH, Hautklin, Beurhausstr 40, D-44137 Dortmund, Germany

来源：

DERMATOLOGIE | 2024年 / 75卷 / 09期

关键词：

Analgesie; Vaccination; COVID-19; WHO Analgesic Ladder; Varicella zoster virus infection; Analgesia; DOUBLE-BLIND; 5-PERCENT; EFFICACY; PAIN;

D O I：

10.1007/s00105-024-05367-y

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Herpes zoster (HZ) is a common disease caused by reactivation of varicella zoster virus. Diagnosis is usually based on the typical clinical presentation. Standard treatment includes antiviral, topical and analgesic therapies. As a complication, postherpetic neuralgia (PHN) can result from acute HZ infection, particularly in older and/or immunocompromised people. This can seriously impair the quality of life of those affected and requires adequate analgesia. In addition to the genesis, clinical presentation and treatment recommendations for HZ and PHN, this article also deals in particular with the vaccination prophylaxis recommended by the standing vaccination commission of the Robert Koch Institute (STIKO).

引用

页码：733 / 742

页数：10

共 35 条

[1]

AWMF-S2k-Leitlinie, 2019, Diagnostik und Therapie des Pemphigus vulgaris/foliaceus und des bullosen Pemphigoids

[2]

Basler HD, 2006, SCHMERZ, V20, P519, DOI 10.1007/s00482-006-0490-7

[3] Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007-2018 [J].

Batram, Manuel ;

Witte, Julian ;

Schwarz, Magdalena ;

Hain, Johannes ;

Ultsch, Bernhard ;

Steinmann, Maren ;

Bhavsar, Amit ;

Wutzler, Peter ;

Criee, Carl-Peter ;

Hermann, Christiane ;

Wahle, Klaus ;

Fuechtenbusch, Martin ;

Greiner, Wolfgang .

DERMATOLOGY AND THERAPY, 2021, 11 (03) :1009-1026

[4] Topical 5% Lidocaine (Lignocaine) Medicated Plaster Treatment for Post-Herpetic Neuralgia Results of a Double-Blind, Placebo-Controlled, Multinational Efficacy and Safety Trial [J].

Binder, Andreas ;

Bruxelle, Jean ;

Rogers, Peter ;

Hans, Guy ;

Boesl, Irmgard ;

Baron, Ralf .

CLINICAL DRUG INVESTIGATION, 2009, 29 (06) :393-408

[5] Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors [J].

Choi, Wonho ;

Ahn, Soo Min ;

Kim, Yong-Gil ;

Lee, Chang-Keun ;

Yoo, Bin ;

Hong, Seokchan .

CLINICAL RHEUMATOLOGY, 2022, 41 (06) :1659-1663

[6] The safety of JAK-1 inhibitors [J].

Clarke, Benjamin ;

Yates, Mark ;

Adas, Maryam ;

Bechman, Katie ;

Galloway, James .

RHEUMATOLOGY, 2021, 60 :II24-II30

[7] The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study [J].

Cotton, S. J. ;

Belcher, J. ;

Rose, P. ;

Jagadeesan, S. K. ;

Neal, R. D. .

BRITISH JOURNAL OF CANCER, 2013, 108 (03) :721-726

[8] Cigarette smoking and risk of herpes zoster: a population-based cohort study in Taiwan [J].

Dai, Y. -X. ;

Yeh, F. -Y. ;

Shen, Y. -J. ;

Tai, Y. -H. ;

Huang, N. ;

Chang, Y. -T. ;

Chen, T. -J. ;

Li, C. -P. ;

Wu, C. -Y. .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021, 46 (07) :1293-1298

[9]

Fried RE, 2013, NEW ENGL J MED, V369, P1766, DOI [10.1056/NEJMc1310369, 10.1056/NEJMcp1302674]

[10]

Hope-Simpson R E, 1975, J R Coll Gen Pract, V25, P571

← 1 2 3 4 →